Altre lingue Huadong Medicine Co., Ltd

Azioni

000963

CNE0000011S1

Prezzo di chiusura Shenzhen S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
32,77 ^CNY	+0,06%		+3,97%	-20,96%

25/04	Huadong Medicine Co., Ltd riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
18/04	L'utile di Huadong Medicine per il 2023 salta del 14%	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Huadong Medicine's 2023 Profit Jumps 14%	18/04
Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
El primer medicamento chino bioequivalente a Ozempic solicita su aprobación	03/04
China's first biosimilar Ozempic drug applies for approval	03/04
Huadong Medicine to Build 2 Billion Yuan Biopharma Innovation Center	09/02
Huadong Medicine to Invest 2 Billion Yuan in Biopharma Innovation Center	09/02
Huadong Medicine's 2023 Profit to Climb Up to 14.5%	01/02
Huadong Medicine Eyes Exclusive Marketing Rights for Cancer Drug Senaparib in China for 290 Million Yuan	21/12
Huadong Medicine's Unit Gains Chinese Drug Regulator's Nod to Trial Sirolimus Oral Solution	06/12
Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd., Hangzhou Gongshu State Investment Industry Development Co., Ltd.	15/11
Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm	14/11
Huadong Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23
Huadong Medicine's Unit Gets Nod to Test Weight Management Drug; Shares Up 3%	15/09/23
MC2 Therapeutics and Huadong Announce License, Development and Commercialization Agreement for Wynzora Cream in Greater China	01/09/23
Huadong Medicine Enters Exclusive Licensing Agreement with Denmark’s MC2	01/09/23
CARsgen Announced 2023 Interim Results	23/08/23
Huadong Medicine’s H1 Profit Rises 7%; EPS, Revenue Miss Forecasts	16/08/23
Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	15/08/23
Huadong Medicine Buys Rights to US Skincare Drug For $100 Million	14/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Huadong Medicine Co., Ltd

Azioni

000963

CNE0000011S1

Altre lingue

Filtri